Nucleoside News and Research

RSS

SARS-CoV-2 mRNA vaccines do not stimulate interferon stimulatory gene expression in Aicardi Goutières Syndrome patients

A new study aimed to evaluate the immunostimulatory potential of mRNA vaccines in AGS patients.

23 May 2022

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

A new study has revealed that ATV006, which is a 5′-hydroxyl-isobutyryl prodrug, possesses extraordinary oral pharmaco-kinetic (PK) profiles in rats and cynomolgus monkeys and exhibited significant antiviral activity against ancestral SARS-COV-2 strain as well as VOCs.

20 May 2022

sCPD9: a SARS-CoV-2 nasal vaccine candidate that may have superior efficacy

...

19 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

SARS-CoV-2 develops partial resistance to the antiviral drug remdesivir in cell culture

The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.

5 May 2022

Artificial circular RNAs found to bypass cellular antiviral responses

Researchers produced artificial circular ribonucleic acid sponges in a permuted intron-exon system and showed that these did not activate innate immunity.

29 Apr 2022

Antibody response to Pfizer-BioNTech COVID-19 vaccine over 6 months

A new study published in PLoS ONE characterizes the antibody response to BNT162b2, the Pfizer-BioNTech COVID-19 vaccine

20 Apr 2022

Oral version of remdesivir could extend its reach and benefits to COVID-19 patients

Scientists at the University of North Carolina at Chapel Hill are testing a new route for remdesivir, a pill form of the COVID-19 treatment that’s given to half of all hospitalized patients with the disease.

22 Mar 2022

Innate and adaptive immune responses to BNT162b2 vaccination in mice

Researchers analyzed the innate and adaptive responses to the mRNA-based BNT162b2 COVID-19 vaccine in mice.

18 Mar 2022

Exploring biomedical literature and clinical trial records to identify new drug combinations for COVID-19 treatment

Researchers extensively searched publicly available SARS-CoV-2 biomedical literature to identify drug combinations that could effectively treat COVID-19.

7 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

A new study describes the efficacy of adenosine receptor agonists in the treatment of SARS-CoV-2 infection.

2 Mar 2022

Study finds MK-4482 inhibits replication of multiple SARS-CoV-2 variants of concern in Syrian hamster COVID-19 model

Researchers found that an antiviral drug, was effective against SARS-CoV-2 variants, including the recently emerged Omicron variant, in Syrian hamsters.

1 Mar 2022

Molecular insights on the possible connection of SARS-CoV-2 and nicotinic acetylcholine receptors

A recent study assessed the mechanism by which SARS-CoV-2 Omicron and Alpha VOCs inhibit the SARS-CoV-2 spike protein and mitigate the risk of a multisystem inflammatory syndrome in children.

28 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

RNA capping mechanism of SARS-CoV-2 unveiled

In a recent study posted to the bioRxiv* preprint server, researchers elucidated the mechanism of ribonucleic acid (RNA) capping in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

14 Feb 2022

Researchers identify a powerful combination of antivirals to treat COVID-19

Researchers at the University of Maryland School of Medicine and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19.

14 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

The recent success of Paxlovid has encouraged researchers to develop new anti-covid drugs. With this in mind, scientists from the University of Pennsylvania have been investigating a new synergistic treatment. Their research is released early as an unedited version of the manuscript to be published in the journal Nature.

9 Feb 2022